SK279237B6 - Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl - Google Patents

Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl Download PDF

Info

Publication number: SK279237B6
Authority: SK; Slovakia
Prior art keywords: alcohol; amperoside; effect; piperazinecarboxamide; fluorophenyl
Prior art date: 1991-03-22

Application number

SK3449-92A

Other languages

English (en)

Slovak (sk)

Other versions

SK344992A3 (en

Inventor

Anders Bj�Rk

Erik Christensson

Original Assignee

Kabi Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-22

Filing date

1992-03-23

Publication date

1998-08-05

1992-03-23 Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab

1995-11-08 Publication of SK344992A3 publication Critical patent/SK344992A3/sk

1998-08-05 Publication of SK279237B6 publication Critical patent/SK279237B6/sk

Links

NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 title claims abstract description 8
229950000388 amperozide Drugs 0.000 title abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 50
239000003814 drug Substances 0.000 claims abstract description 27
239000000126 substance Substances 0.000 claims abstract description 27
229940079593 drug Drugs 0.000 claims abstract description 20
206010013663 drug dependence Diseases 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 8
208000011117 substance-related disease Diseases 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 5
230000003533 narcotic effect Effects 0.000 claims description 4
208000007848 Alcoholism Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
201000007930 alcohol dependence Diseases 0.000 claims description 2
208000024891 symptom Diseases 0.000 abstract description 5
239000004081 narcotic agent Substances 0.000 abstract description 4
239000002398 materia medica Substances 0.000 abstract 1
230000000631 nonopiate Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 24
150000001875 compounds Chemical class 0.000 description 19
230000000694 effects Effects 0.000 description 19
229960003920 cocaine Drugs 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 8
241000700159 Rattus Species 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000006399 behavior Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
229940127222 serotonin uptake blocker Drugs 0.000 description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 5
229960002073 sertraline Drugs 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
230000037396 body weight Effects 0.000 description 4
235000013305 food Nutrition 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940049706 benzodiazepine Drugs 0.000 description 3
150000001557 benzodiazepines Chemical class 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229960002791 zimeldine Drugs 0.000 description 3
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
208000022497 Cocaine-Related disease Diseases 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
206010057852 Nicotine dependence Diseases 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
208000025569 Tobacco Use disease Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
201000006145 cocaine dependence Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008918 emotional behaviour Effects 0.000 description 2
229960004756 ethanol Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
229950010883 phencyclidine Drugs 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000003772 serotonin uptake inhibitor Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
PTPTUSSTCDZDGG-UHFFFAOYSA-N 2-(4,4-diphenylbutyl)piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1CCCC(C=1C=CC=CC=1)C1=CC=CC=C1 PTPTUSSTCDZDGG-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
102000004300 GABA-A Receptors Human genes 0.000 description 1
108090000839 GABA-A Receptors Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940080435 lactose 250 mg Drugs 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004630 mental health Effects 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910052717 sulfur Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000007593 synaptic transmission, glutaminergic Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Addiction (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK3449-92A 1991-03-22 1992-03-23 Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl SK279237B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9100860A SE9100860D0 (sv)	1991-03-22	1991-03-22	New use
PCT/SE1992/000182 WO1992016211A1 (en)	1991-03-22	1992-03-23	New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (2)

Publication Number	Publication Date
SK344992A3 SK344992A3 (en)	1995-11-08
SK279237B6 true SK279237B6 (sk)	1998-08-05

Family

ID=20382242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK3449-92A SK279237B6 (sk)	1991-03-22	1992-03-23	Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl

Country Status (24)

Country	Link
US (2)	US5434156A (pt)
EP (1)	EP0538422B1 (pt)
JP (1)	JP3221611B2 (pt)
KR (1)	KR100196674B1 (pt)
AT (1)	ATE199057T1 (pt)
AU (1)	AU653797B2 (pt)
BG (1)	BG61829B1 (pt)
BR (1)	BR9204969A (pt)
CA (1)	CA2083505C (pt)
CZ (1)	CZ282222B6 (pt)
DE (1)	DE69231680T2 (pt)
DK (1)	DK0538422T3 (pt)
EE (1)	EE02973B1 (pt)
ES (1)	ES2154261T3 (pt)
GR (1)	GR3035805T3 (pt)
HU (2)	HU217833B (pt)
IE (1)	IE920920A1 (pt)
NO (1)	NO301311B1 (pt)
PT (1)	PT100279B (pt)
RO (1)	RO109702B1 (pt)
RU (1)	RU2095062C1 (pt)
SE (1)	SE9100860D0 (pt)
SK (1)	SK279237B6 (pt)
WO (1)	WO1992016211A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9100860D0 (sv) *	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use
SE9201239D0 (sv)	1992-04-21	1992-04-21	Kabi Pharmacia Ab	Agents for treating substance abuse disorders
JP3571114B2 (ja) *	1995-07-11	2004-09-29	ポーラ化成工業株式会社	麻薬拮抗剤
US6265393B1 (en)	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
US6090780A (en) *	1999-04-07	2000-07-18	Chandon Prasad	Histidyl-proline diketopiperazine and method of use
USRE39921E1 (en)	1999-10-07	2007-11-13	Smithkline Beecham Corporation	Chemical compounds
GB9923748D0 (en)	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
KR100712570B1 (ko) *	2001-01-17	2007-05-02	하이디엄, 인크.	알콜 의존성 치료약의 제조에서 플루마제닐의 용도
US20050192271A1 (en) *	2003-07-15	2005-09-01	Hythiam, Inc.	Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) *	2001-02-15	2009-08-04	Juan Jose Legarda Ibanez	Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US7183410B2 (en) *	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US20030060475A1 (en) *	2001-08-10	2003-03-27	Boehringer Ingelheim Pharma Kg	Method of using flibanserin for neuroprotection
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
GB0203020D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
GB0203022D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
WO2003066589A1 (en)	2002-02-08	2003-08-14	Glaxo Group Limited	Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
US20050239798A1 (en) *	2004-04-22	2005-10-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) *	2004-04-22	2011-08-11	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for the treatment of sexual disorders II
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) *	2004-09-03	2008-04-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	注意欠如活動過多障害の治療方法
WO2006096439A2 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006119884A2 (en) *	2005-05-06	2006-11-16	Boehringer Ingelheim International Gmbh	Method for the treatment of drug abuse with flibanserin
US20060264512A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of sexual dysfunction due to medical conditions
US20060264511A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja)	2005-08-03	2009-01-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) *	2005-10-29	2013-12-24	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) *	2005-10-29	2007-05-31	Angelo Ceci	Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) *	2005-11-08	2007-05-10	Stephane Pollentier	Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2008013827A (es) *	2006-05-09	2008-11-10	Boehringer Ingelheim Int	Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EP2037927B1 (en) *	2006-06-30	2010-01-27	Boehringer Ingelheim International GmbH	Flibanserin for the treatment of urinary incontinence and related diseases
WO2008006838A1 (en) *	2006-07-14	2008-01-17	Boehringer Ingelheim International Gmbh	Use of flibanserin for the treatment of sexual disorders in females
JP5793828B2 (ja)	2006-08-14	2015-10-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) *	2006-08-14	2008-03-07	Boehringer Ingelheim Int	Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) *	2006-08-25	2009-05-08	베링거 인겔하임 인터내셔날 게엠베하	제어 방출 시스템 및 이의 제조방법
CL2008002693A1 (es) *	2007-09-12	2009-10-16	Boehringer Ingelheim Int	Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO154582C (no) *	1978-10-20	1986-11-05	Ferrosan Ab	Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) *	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use

1991
- 1991-03-22 SE SE9100860A patent/SE9100860D0/xx unknown
1992
- 1992-03-23 ES ES92907159T patent/ES2154261T3/es not_active Expired - Lifetime
- 1992-03-23 AT AT92907159T patent/ATE199057T1/de not_active IP Right Cessation
- 1992-03-23 SK SK3449-92A patent/SK279237B6/sk unknown
- 1992-03-23 DE DE69231680T patent/DE69231680T2/de not_active Expired - Fee Related
- 1992-03-23 RU RU9292016400A patent/RU2095062C1/ru not_active IP Right Cessation
- 1992-03-23 PT PT100279A patent/PT100279B/pt not_active IP Right Cessation
- 1992-03-23 CZ CS923449A patent/CZ282222B6/cs not_active IP Right Cessation
- 1992-03-23 HU HU9203632A patent/HU217833B/hu not_active IP Right Cessation
- 1992-03-23 JP JP50658392A patent/JP3221611B2/ja not_active Expired - Fee Related
- 1992-03-23 AU AU14280/92A patent/AU653797B2/en not_active Ceased
- 1992-03-23 WO PCT/SE1992/000182 patent/WO1992016211A1/en not_active Ceased
- 1992-03-23 BR BR9204969A patent/BR9204969A/pt not_active Application Discontinuation
- 1992-03-23 HU HU9203632A patent/HU9203632D0/hu unknown
- 1992-03-23 KR KR1019920702939A patent/KR100196674B1/ko not_active Expired - Fee Related
- 1992-03-23 CA CA002083505A patent/CA2083505C/en not_active Expired - Fee Related
- 1992-03-23 IE IE092092A patent/IE920920A1/en not_active IP Right Cessation
- 1992-03-23 EP EP92907159A patent/EP0538422B1/en not_active Expired - Lifetime
- 1992-03-23 US US07/949,869 patent/US5434156A/en not_active Expired - Fee Related
- 1992-03-23 DK DK92907159T patent/DK0538422T3/da active
- 1992-03-23 RO RO92-01457A patent/RO109702B1/ro unknown
- 1992-11-20 BG BG97108A patent/BG61829B1/bg unknown
- 1992-11-23 NO NO924502A patent/NO301311B1/no unknown
1994
- 1994-11-17 EE EE9400358A patent/EE02973B1/xx not_active IP Right Cessation
1995
- 1995-04-25 US US08/428,899 patent/US5618817A/en not_active Expired - Fee Related
2001
- 2001-04-27 GR GR20010400653T patent/GR3035805T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU1428092A (en)	1992-10-21
HU9203632D0 (en)	1993-03-29
CA2083505A1 (en)	1992-09-23
DK0538422T3 (da)	2001-05-07
SE9100860D0 (sv)	1991-03-22
CA2083505C (en)	2003-06-10
US5618817A (en)	1997-04-08
PT100279B (pt)	1999-06-30
NO924502L (no)	1992-11-23
EP0538422A1 (en)	1993-04-28
CZ344992A3 (en)	1994-02-16
NO924502D0 (no)	1992-11-23
HUT64696A (en)	1994-02-28
NO301311B1 (no)	1997-10-13
AU653797B2 (en)	1994-10-13
US5434156A (en)	1995-07-18
CZ282222B6 (cs)	1997-06-11
DE69231680D1 (de)	2001-03-15
KR100196674B1 (ko)	1999-06-15
GR3035805T3 (en)	2001-07-31
HU217833B (hu)	2000-04-28
JP3221611B2 (ja)	2001-10-22
BR9204969A (pt)	1993-07-27
WO1992016211A1 (en)	1992-10-01
ES2154261T3 (es)	2001-04-01
IE920920A1 (en)	1992-09-23
BG97108A (bg)	1994-03-24
EE02973B1 (et)	1997-04-15
BG61829B1 (bg)	1998-07-31
RO109702B1 (ro)	1995-05-30
EP0538422B1 (en)	2001-02-07
RU2095062C1 (ru)	1997-11-10
JPH05507731A (ja)	1993-11-04
PT100279A (pt)	1993-07-30
SK344992A3 (en)	1995-11-08
KR930700108A (ko)	1993-03-13
ATE199057T1 (de)	2001-02-15
DE69231680T2 (de)	2001-06-07

Publication	Publication Date	Title
SK279237B6 (sk)	1998-08-05	Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl
IE83379B1 (en)		New use of diphenylbutylpiperazinecarboxamides in the treatment of substance abuse
US5565455A (en)	1996-10-15	Method for treating substance abuse disorders
KR101477043B1 (ko)	2014-12-29	디스키네시아의 치료 또는 예방제
US5629336A (en)	1997-05-13	Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
WO1992014464A1 (en)	1992-09-03	Use of sigma receptor antagonists for treatment of cocaine abuse
AU629688B2 (en)	1992-10-08	Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
US6221858B1 (en)	2001-04-24	Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
US20010053786A1 (en)	2001-12-20	Methods for treating addictive disorders
MXPA98009265A (en)	1999-07-06	Piridil- and pyrimidil-piperazines in the treatment of disorders from the abuse of sustain
PT97961B (pt)	1998-11-30	Processo para a preparacao de composicoes farmaceuticas contendo derivados de 4-{bis-(halogenofenil)-metileno}-1-piperidinilo apropriadas para o tratamento do vicio de ingestao de drogas que originam habituacao